A detailed history of Captrust Financial Advisors transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 128,446 shares of VYGR stock, worth $688,470. This represents 0.0% of its overall portfolio holdings.

Number of Shares
128,446
Previous 128,941 0.38%
Holding current value
$688,470
Previous $1.02 Million 26.3%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.77 - $9.27 $2,856 - $4,588
-495 Reduced 0.38%
128,446 $751,000
Q2 2024

Aug 14, 2024

SELL
$7.42 - $10.54 $460 - $653
-62 Reduced 0.05%
128,941 $1.02 Million
Q1 2024

May 15, 2024

BUY
$7.15 - $10.84 $742,541 - $1.13 Million
103,852 Added 412.91%
129,003 $1.2 Million
Q4 2023

Feb 14, 2024

BUY
$6.28 - $8.81 $19,788 - $27,760
3,151 Added 14.32%
25,151 $212,000
Q2 2023

Aug 14, 2023

BUY
$6.94 - $13.99 $152,680 - $307,780
22,000 New
22,000 $251,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $207M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.